<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Peasland A</submitter><funding>Cancer Research UK</funding><funding>NCI NIH HHS</funding><pagination>372-81</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3172902</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>105(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a key role in the signalling of stalled replication forks and DNA damage to cell cycle checkpoints and DNA repair. It has long been recognised as an important target for cancer therapy but inhibitors have proved elusive. As NU6027, originally developed as a CDK2 inhibitor, potentiated cisplatin in a CDK2-independent manner we postulated that it may inhibit ATR.&lt;h4>Methods&lt;/h4>Cellular ATR kinase activity was determined by CHK1 phosphorylation in human fibroblasts with inducible dominant-negative ATR-kinase dead expression and human breast cancer MCF7 cells. Cell cycle effects and chemo- and radiopotentiation by NU6027 were determined in MCF7 cells and the role of mismatch repair and p53 was determined in</pubmed_abstract><journal>British journal of cancer</journal><pubmed_title>Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.</pubmed_title><pmcid>PMC3172902</pmcid><funding_grant_id>R01 CA148747</funding_grant_id><pubmed_authors>Hopkins A</pubmed_authors><pubmed_authors>Beale G</pubmed_authors><pubmed_authors>Peasland A</pubmed_authors><pubmed_authors>Sarkaria J</pubmed_authors><pubmed_authors>Curtin NJ</pubmed_authors><pubmed_authors>Edmondson RJ</pubmed_authors><pubmed_authors>Wang LZ</pubmed_authors><pubmed_authors>Cliby WA</pubmed_authors><pubmed_authors>Kyle S</pubmed_authors><pubmed_authors>Rowling E</pubmed_authors><pubmed_authors>Chen T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.</name><description>&lt;h4>Background&lt;/h4>The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a key role in the signalling of stalled replication forks and DNA damage to cell cycle checkpoints and DNA repair. It has long been recognised as an important target for cancer therapy but inhibitors have proved elusive. As NU6027, originally developed as a CDK2 inhibitor, potentiated cisplatin in a CDK2-independent manner we postulated that it may inhibit ATR.&lt;h4>Methods&lt;/h4>Cellular ATR kinase activity was determined by CHK1 phosphorylation in human fibroblasts with inducible dominant-negative ATR-kinase dead expression and human breast cancer MCF7 cells. Cell cycle effects and chemo- and radiopotentiation by NU6027 were determined in MCF7 cells and the role of mismatch repair and p53 was determined in</description><dates><release>2011-01-01T00:00:00Z</release><publication>2011 Jul</publication><modification>2025-04-18T13:21:55.239Z</modification><creation>2019-03-27T00:43:55Z</creation></dates><accession>S-EPMC3172902</accession><cross_references><pubmed>21730979</pubmed><doi>10.1038/bjc.2011.243</doi></cross_references></HashMap>